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Summary 
Objective. Hydrogen sulfide (H2S), the third gasotransmitter together with NO and CO, is emerging as a regulator of 
inflammation. To test if it might offer therapeutic value in the treatment of osteoarthritis (OA) we evaluated the 
effects of two exogenous sources of H2S, NaSH and GYY4137, on inflammation and catabolic markers that 
characterize OA. 
Method. Human chondrocytes (CHs) were isolated from OA tissue. Cells were stimulated with a pro-inflammatory 
cytokine (interleukin-1β, IL1β, 5 ng/ml) and the ability of the two H2S sources to ameliorate its effects on the cells 
was tested. Nitric oxide (NO) production was quantified through the Griess reaction. Protein levels of inducible NO 
synthase (NOS2) and matrix metalloproteinase 13 (MMP13) were visualized through immunocytochemistry (ICC). 
Relative mRNA expression was quantified with qRT-PCR. Prostaglandin-2 (PGE-2), interleukin 6 (IL6) and MMP13 
levels were measured with specific EIAs. NFκB nuclear translocation was visualized with immunofluorescence. 
Results. Both H2S sources led to significant reductions in NO, PGE-2, IL6 and MMP13 released by the cells and at 
the protein level. This was achieved by downregulation of relevant genes involved in the synthesis routes of these 
molecules, namely NOS2, cyclooxigenase-2 (COX2), prostaglandin E synthase (PTGES), IL6 and MMP13. NFκB 
nuclear translocation was also reduced. 
Conclusion. NaSH and GYY4137 show anti-inflammatory and anti-catabolic properties when added to IL1β 
activated osteoarthritic CHs. Supplementation with exogenous H2S sources can regulate the expression of relevant 
genes in OA pathogenesis and progression, counteracting IL1β pro-inflammatory signals that lead to cartilage 
destruction in part by reducing NFκB activation. 
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Introduction 
Osteoarthritis (OA) is a degenerative joint pathology that results in severe pain and loss of function. With 
a high prevalence among the elderly population, it is one of the three most common causes of 
incapacitation in people younger than 601, 2 and 3. OA is characterized by a progressive loss of articular 
hyaline cartilage in the joints and although its complete etiology is not known, it is generally accepted 
that OA is caused by a deregulation of the catabolic and anabolic processes that regulate cartilage matrix 
synthesis. Chondrocytes (CHs), the only cell type present in cartilage, are responsible for producing and 
maintaining the extracellular matrix (ECM) which, normally, has a very low turnover rate. Loss of this 
equilibrium is not the result of a single mechanism but of a complex interplay between abnormal 
mechanical stresses, increased amounts of proinflammatory cytokines and/or other insults. 
OA has not traditionally been considered an inflammatory disease4, but many studies confirm the 
implication of several pro-inflammatory mediators, such as interleukin-1β (IL1β) and tumor necrosis 
factor-α (TNF-α), in the progression of OA5. For instance, elevated IL1β levels are found in the synovial 
fluid of OA patients and IL1β gene expression is upregulated in OA tissue. Additionally, IL1β activates 
the synthesis and release of matrix metalloproteinases (MMPs) leading to matrix breakdown6. 
Nitric oxide (NO) has also been implicated in the pathophysiology of OA. NO is produced from l-
arginine by NO synthases. Three isoforms are known, two are constitutively expressed (Neuronal NO, 
nNOS and endothelial NO, eNOS) and the expression of the third isoform, NOS2, is induced in cellular 
stress situations and by IL1β and TNF-α. At normal physiological concentrations NO influences vascular 
tone, cell adhesion and vascular permeability7, but, it can also exert potential toxic effects. Like IL1β, NO 
has been shown to inhibit the synthesis of cartilage matrix components. Excess production of NO is also 
linked to oxidative damage8. 
In addition to the effects above, OA is also characterized by an increase in PGEs production. PGEs are 
produced from arachidonic acid in a cascade that involves cyclooxygenases 1 and 2 (COX1 and COX2) 
which produce the intermediate form PGE H-2. PGE E synthase (PTGES) converts PG (H)-2 to PGE E−2 
(PGE-2) downstream of COX1 and COX29. OA cartilage produces high quantities of PGE-2 and PTGES 
is also upregulated, together with COX2, in IL1β and TNF-α stimulated CHs5 and 9. 
All these factors, probably synergistically10, contribute to the increase in catabolic processes that lead 
to cartilage destruction in OA. 
Hydrogen sulfide (H2S) is emerging as a potential regulator of inflammation and it might offer 
therapeutic value in the treatment of OA. H2S has been traditionally classified as a toxic gas
11 but in the 
past 10–15 years, scientific opinion has changed as more reports on its biological activity were published 
and it is now considered as a biologically relevant molecule12 and 13. H2S is synthesized endogenously in 
mammals from l-cysteine by at least two pyridoxal-5′-phosphate dependent enzymes, cystathionine β-
synthase (CBS) and cystathionine γ-lyase (CTH) and to a lower extent by mercaptopyruvate 
sulfurtransferase (MPST). Together with NO and CO, H2S has been identified as a gasotransmitter
14 and 15 
and as such it can permeate cellular membranes without a specific transporter. Low (micromolar) levels 
of H2S have been found to be cytoprotective in several disease models, whereas several inflammation 
animal models have found increased endogenous levels of H2S (reviewed in
12 and 13). With respect to 
inflammatory rheumatic diseases, Whiteman et al. 16 were able to detect H2S in the synovial fluid from 
patients with rheumatoid arthritis (RA) and OA as well as in plasma from normal controls (37.6 μM). 
Levels from RA patients (62.41 μM) were significantly increased over those of the OA group (25.1 μM). 
This group has also recently shown that human articular CHs and mesenchymal progenitor cells 
synthesize CBS and CTH, and that their expression was induced by various cytokines, including IL1β 17. 
Therefore, even though its role has not been clearly elucidated yet, evidence suggests that H2S may have 
an important function in inflammation and it might be of interest as a therapeutic agent in diseases that 
have an inflammatory component, such as OA. 
In this study, two exogenous sources of H2S, NaSH (a fast dissolving salt) and GYY4137 (as a slow 
releasing agent), were added to cultures of IL1β-stimulated human articular CHs isolated from 
osteoarthritic tissue. Concentrations of the H2S sources ranged from 0.05 to 1 mM and their effects on 
several markers of inflammation and cartilage degradation were investigated. Also, since activation of 
nuclear factor-κB (NFκB) is directly responsible for the upregulation of several proinflammatory 
cytokines and enzymes, including NOS2, COX2 and IL618 and 19, this signaling route was investigated as a 
possible mechanism of action for H2S. 
Methods 
Materials 
Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS) and Penicillin/Streptomycin 
(P/S) were from Gibco (Gibco, Madrid, Spain). Culture flasks and other disposable plastic were 
purchased from BD (BD Bioscience, Madrid, Spain). Sodium hydrosulfide (NaSH), sodium nitrite, 
human recombinant interleukin-1β (IL1β), trypsin and collagenase were purchased from Sigma–Aldrich 
(Sigma–Aldrich Química S.A, Madrid Spain). GYY4137 (Morpholin-4-ium 4 
methoxyphenyl(morpholino phosphinodithioate)) was purchased from Santa Cruz Biotechnology, 
Heidelberg, Germany. AlamarBlue® was purchased from Invitrogen S.A., Barcelona, Spain. The Griess 
reagent was from Enzo Life Science, Madrid, Spain. The PGE-2 EIA was purchased from GE Healthcare, 
Barcelona, Spain and the ELISAs for matrix metalloproteinase-13 (MMP13), and interleukin-6 (IL6) 
were purchased from R&D systems (Madrid, Spain). Antibodies for NOS2, MMP13 and NFκB p65 were 
from Abcam (Abcam plc, Cambridge, UK), Thermo Scientific (Cienytech, A Coruña, Spain) and Santa 
Cruz Biotechnology, respectively. Reagents for immunocytochemistry (ICC) were from Dako (Dako, 
Barcelona, Spain) and reagents for molecular biology were from Invitrogen (Invitrogen S.A. Barcelona, 
Spain), unless otherwise stated. 
Tissue selection and cell culture 
Osteoarthritic cartilage donors were patients of the Orthopedic Service of the University Hospital A 
Coruña (CHUAC) that had knee or hip replacement surgery (seven men and six women, age 77.5 ± 10.0 
years old). The local ethics committee approved the study and written informed consent was obtained 
from all the patients. CHs were isolated by sequential enzymatic digestion from human articular cartilage 
as described previously20. Briefly, cartilage sections were washed with saline and minced into small 
pieces. This was then incubated with trypsin at 37 °C for 10 min, followed by 12–16 h incubation with 
type IV clostridial collagenase (2 mg/ml) in DMEM with 5% FBS and 1% P/S. Isolated cells were 
centrifuged and re-suspended in expansion medium (DMEM containing 10% FBS and 1% P/S) and 
allowed to grow until pre-confluent at 37 °C in a humidified incubator with 5% CO2. The cells used for 
the experiments were routinely checked for production of collagen type II and aggrecan to ensure they 
maintained a chondrocytic phenotype. 
Cell stimulation and treatment experiments 
Only cells from passage two were used. For all experiments cells were incubated in expansion medium 
during 24 h for adherence, then the medium was changed to depleted medium (DMEM containing 0.5% 
FBS and 1% P/S) with the different concentrations, 0 (Basal), 100, 200, 500 or 1,000 μM of one of the 
sulfide sources (NaSH or GYY4137) and with or without IL-1β (5 ng/ml), for an additional incubation 
time of either 24 h (cell viability) or 48 h (rest of the experiments). 
Cell viability assay 
The effect of the sulfide-releasing compounds on CH viability was determined with AlamarBlue® cell 
viability reagent following manufacturer instructions. Cells were seeded (5·104/well, 96 well plates) and 
treated as described above. AlamarBlue® was added to the cells in a volume equivalent to 10% of the total 
volume. Reduction of AlamarBlue® was measured with a spectrophotometer (Nanoquant Infinite M200, 
Tecan Ibérica Instrumentación S.L Barcelona, Spain) at 570 nm and with 600 nm as a reference, after 4 h 
of incubation. 
NO production assay 
The Griess reaction was used to determine the effects of NaSH and GYY4137 on NO production in IL1β-
stimulated CHs21. CHs were plated (5·104/well, 96 well plates) and treated as described above. Culture 
supernatants (50 μl) were collected for nitrite measurements and mixed with 50 μl of Griess reagent. NO 
formation was detected by nitrite accumulation using sodium nitrite as standard. Optical density was 
measured at 570 nm in a Nanoquant Infinite M200 spectrophotometer (Tecan). 
NOS2 and MMP13 ICC 
The effect of NaSH and GYY4137 on the accumulation of NOS2 and MMP13 proteins in IL1β-
stimulated CHs was measured through ICC. Cells were seeded (3·104/well, 8 well chamber slides), 
treated as described above and then fixed in acetone at 4 °C for 10 min. The endogenous peroxidase 
activity was blocked with Dako Real™ peroxidase blocking solution during 10 min at room temperature. 
Cells were washed with phosphate buffer solution (PBS) and incubated with either rabbit-antihuman 
polyclonal NOS2 antibody or mouse-antihuman MMP13 monoclonal antibody. The rabbit/mouse 
peroxidase/DAB DAKO REAL™ EnVision™ detection kit was used to determine antigen–antibody 
interactions. Slides were dehydrated in graded alcohol, cleared in xylene and mounted in DePeX (Gurr®, 
VWR International Eurolab S.L., Barcelona, Spain). A negative control was included by omitting the 
primary antibody in one of the wells. Slides were then visualized in an Olympus Dx61 optical 
microscope (Olympus España S.A.U., Barcelona, Spain). 
NFκB immunofluorescence 
For the NFκB immunofluorescence assay cells were seeded (3·104/well, 8 well chamber slides) and 
treated as described above, but for only 45 min, to be able to detect NFκB translocation to the cells nuclei 
and then fixed in paraformaldehyde at 4 °C for 10 min. Cells were then treated with 3% Triton-X for 
5 min, washed subsequently with water and PBS. Cell were incubated with the antibody for 3 h in the 
dark, counterstained with DAPI for 30 min and mounted with Glycergel mounting medium. 
PGE-2, IL6 and MMP13 ELISA assays 
The effect of the addition of the H2S sources on PGE-2, MMP13 and IL6 production in IL1β–stimulated 
CHs was quantified on cell supernatants using specific enzyme immunoassays, following their 
manufacturer instructions. Cells were seeded (5·104/well, 96 well plates) and treated as described above. 
The calibration curves for PGE-2 EIA, the MMP13 ELISA and the IL6 ELISA spanned from 50 to 
6,400 ng/ml, from 33 to 4,200 pg/ml and from 9.4 to 1,200 pg/ml, respectively. Samples were diluted 
accordingly. 
qRT-PCR analyses 
The effect of NaSH and GYY4137 on the expression of the genes included in Table I in IL1β-stimulated 
CHs was quantified using qRT-PCR. Cells were seeded (3·105/well, 12 well plates) and treated as 
described above. Total RNA was isolated using Trizol® Reagent, following the manufacturer protocol. 
RNA concentration was quantified at 260 nm using a NanoDrop™ spectrophotometer (Thermo Scientific, 
Madrid, Spain). The A260/A280 ratio was calculated to verify quality and purity. Integrity of RNA was 
verified with an Agilent 2100 Bioanalyzer (Agilent Technologies Spain S.L., Madrid, Spain). Total RNA 
was treated with DNase enzyme (Fermentas, Fisher Scientific, Madrid, Spain) to degrade residual 
genomic DNA. Complementary DNA was synthesized from 0.5 μg of total RNA using SuperScript® 
VILO™ Master Mix in a total volume of 10 μl in a Thermocycler (Gene Amp PCR System 9700, 
Applied Biosystems, Madrid, Spain). qRT-PCR experiments were performed on a LightCycler1 480 
Instrument (Roche, Mannheim, Germany) using Taqman probes (Universal Probe Library set, Roche). 
Primers and probe assays were designed using Roche Assay Design Center available at 
www.universalprobelibrary.com. Designed probe assays are included in Table I. PCR reactions consisted 
of a pre-incubation (95 °C, 10 min) (up to) 45 cycles of amplification including incubation (95 °C 10 s), 
extension (60 °C, 30 s) and cooling (72 °C, 1 s) and final cooling ramp (40 °C, 20 s). HPRT1 
(Hypoxanthine-guanine phosphoribosyltransferase) and TBP (TATA box binding protein) genes were 
used as the reference genes. These genes were previously selected from a reference gene panel using 
GeNorm software. Relative levels of expression were calculated using qBase + software 
(www.BioGazelle.com). Data were normalized against the mean value obtained in unstimulated cells 
(Basal), which was normalized to 1, and were expressed as relative expression levels. 
Table I. Primers and probes used for the qRT-PCR experiments 
Gene RefSeq (mRNA) Primers sequences Position Probe n# Amplicon length (bp) 
      
HPRT1 NM_000194.2 
5′-tgatagatccattcctatgactgtaga-3′ 
5′-caagacattctttccagttaaagttg-3′ 
434–460 
535–560 
22 127 
TBP NM_003194.4 
5′-gcccatagtgatctttgcagt-3′ 
5′-cgctggaactcgtctcacta-3′ 
104–124 
223–242 
67 139 
INOS NM_000625.4 
5′-gctgccaagctgaaattga-3′ 
5′-gatagcgcttctggctcttg-3′ 
3,562–3,580 
3,615–3,634 
68 73 
PTGES NM_004878.4 
5′-ctgggatgacaggcatgaat-3′ 
5′-gactcacatgggagcctttt-3′ 
1,237–1,256 
1,286–1,305 
83 69 
COX2 NM_000963.2 
5′-cttcacgcatcagtttttcaag-3′ 
5′-tcaccgtaaatatgatttaagtccac-3′ 
707–728 
777–802 
23 96 
IL-6 NM_000600.3 
5′-gctgagtacaaaagtcctgatcca-3′ 
5′-ctgcagccactggttctgt-3′ 
548–571 
659–677 
40 130 
MMP13 NM_002427.2 
5′-ccagtctccgaggagaaaca-3′ 
5′-aaaaacagctccgcatcaac-3′ 
909–928 
974–993 
73 85 
      
 
Statistical analyses 
All qRT-PCR experiments were performed with cells from n ≥ 3 biological replicates and duplicate 
technical repeats. Relative expression values were calculated with qBase + software and are expressed as 
the geometric mean and 95% lower and upper limit confidence intervals. Statistical analysis (one-way 
ANOVA followed by a post-hoc test) of these results was done with qBase + software too. For the rest of 
the experiments, results are expressed as mean and 95% lower and upper limit confidence intervals of at 
least three biological replicates and duplicate technical repeats. Statistical analyses were performed with 
R software (version 2.15.2) 22. Data were assayed with one-way ANOVA and a Tukey multiple 
comparisons test. In all cases, a P value lower than 0.05 was considered significant. 
Results 
Cell viability 
Reduction of AlamarBlue® values were normalized with respect to the basal condition which was given 
an arbitrary value of 100%. None of the concentrations of either NaSH or GYY4137 used reduced the 
viability of the OA CHs (Table II). 
Table II. CH viability, as measured with AlamarBlue reagent. Results are mean and 95% confidence intervals (Lower limit, ll, 
upper limit ul) of n = 3 independent experiments performed in duplicate. A Kruskal Wallis rank sum test was performed; for NaSH, 
P = 0.80 and for GYY4137, P = 0.78 
%Viability 
Mean (Ll 95% CI, ul 
95% CI), n = 3 
Basal IL1β H2S compound concentration (μM) 
  50 100 200 500 1,000 
        
NaSH 
100.0 (46.3, 
153.7) 
106.5 (34.5, 
181.4) 
107.2 (54.0, 
156.7) 
103.4 (43.8, 
161.2) 
104.4 (43.6, 
163.1) 
100.0 (42.7, 
157.7) 
98.2 (41.3, 
156,1) 
GYY4137 
100.0 (53.7, 
146.3) 
106.5 (45.7, 
170.8) 
98.9 (50.4, 
150.5) 
94.9 (51.0, 
143.2) 
93.7 (48.1, 
143.5) 
98.6 (54.1, 
143.8) 
99.4 (50.2, 
149.4) 
        
 
Sulfide compounds reduce NO production by downregulating NOS2 gene expression 
Basal production of NO (measured as nitrite) ranged from around 0.06 μM–12 μM (3.92 (1.64, 6.20), 
n = 7, performed in duplicate). Stimulation with IL1β (5 ng/ml) increased in production of NO to values 
that ranged between 23 μM and 133 μM (79.85 (63.70, 96.00), n = 7, performed in duplicate) [ Fig. 1(A) 
and (B)]. Addition of the different concentrations of H2S compounds did not induce the formation of NO 
by itself (results not shown). Both NaSH and GYY4137 induced a dose-dependent reduction on NO 
production in IL1β stimulated cells, with values for 500 μM and 1,000 μM NaSH and GYY4237 being 
significantly lower [ Fig. 1(A) and (B)]. 
NOS2 mRNA expression was quantified with qRT-PCR. Stimulation with IL1β induced NOS2 
mRNA expression and the addition of H2S-releasing agents dose-dependently attenuated this increase, 
however, none of the values were significantly different from the IL1β value. For both NaSH and 
GYY4137, 1,000 μM was the most effective concentration in reducing NOS2 mRNA expression 
[Fig. 1(C) and (D)]. Results obtained through the Griess reaction and those of qRT-PCR were 
corroborated also by ICC [Fig. 1(E)–(M)]. In addition, to ensure that these results were due to the H2S 
released from NaSH and GYY4137, we performed these same experiments with decomposed NaSH and 
GYY4137 (stock solutions were left uncapped in a chemical hood for 10 days). In this case, all effects 
were lost, no reduction was observed in NO production or NOS2 relative expression from the IL1β-
stimulated values (results not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Addition of NaSH (A, C) and GYY4137 (B, D) to IL1β-stimulated CHs reduced nitrite accumulation, as measured through 
the Griess reaction (A and B), NOS2 gene expression, by qRT-PCR (C and D) and NOS2 protein accumulation, by ICC (E–M). 
Values are mean and 95% CI (Lower limit, upper limit, n number in parenthesis, performed in duplicate). In A and B, Kruskal–
Wallis rank sum test was performed followed by multiple comparisons. In C and D, one way ANOVA was performed followed by a 
Tukey post-hoc multiple comparisons test. *P < 0.0001 (cf. Basal group); #P < 0.0001 (cf. IL1β stimulated group), except for C 
where P = 0.0001. ICC images include IL1β-stimulated CHs (G) treated with different concentrations of NaSH (H–J) and GYY4137 
(K–M). A negative ICC control (without primary antibody (E)), as well as unstimulated cells (F), were included for comparison. 
H2S compounds reduce PGE-2 levels by downregulating COX2 and PTGES enzymes 
PGE-2 basal level was 0.25 (0.13, 0.36) ng/ml (n = 3) in the cells. Stimulation with IL1β led to an 
increase up to 64.7 (41.78, 87.66) ng/ml PGE-2. Different concentrations of NaSH and GYY4137 were 
added to the IL1β-stimulated cells to investigate their effect on PGE-2 production [ Fig. 2(A) and (B)]. 
All concentrations tested, except for 1,000 μM NaSH and 50 μM GYY4137, resulted in a significant 
decrease from the IL1β-stimulated cells. When looking at the mRNA expression of the main enzymes 
involved in PGE-2 synthesis, we found a notable dose-dependent reduction in COX2 mRNA expression [ 
Fig. 2(C) and (D)] from the IL1β-induced increase. In particular, the IL1β-induced value was 97.5 (19.5, 
487,9) fold vs Basal and 1,000 μM NaSH and GYY4137 reduced this value to 12.0 (1.6, 89.13) and 7.6 
(0.4, 142,1), respectively, n = 4. Interleukin-1β also induced an elevation of PTGES mRNA expression 
(68.5 (19.8, 236.7) vs Basal) and 1,000 μM NaSH and GYY4137 considerably reduced this value to 16.3 
(3.8, 69.2) and 31.7 (8.3, 120.7), respectively, n = 4 [ Fig. 2(E) and (F)]. 
 
 
 
Fig. 2. PGE E−2 production in IL1β-stimulated CHs declined after treatment with different concentrations of NaSH (A) and 
GYY4137 (B). Concurrently, COX2 (C, D) and PTGES (E–F) mRNA expression in the cells was also reduced due to the addition 
of NaSH (C, E) and GYY4137 (D, F). PGE-2 values, measured with a specific EIA are mean and 95% CI (Lower limit, upper limit, 
n = 3). Relative mRNA expression values were calculated, with respect to the Basal condition with qBase + software, n indicated in 
parenthesis and performed in duplicate. One way ANOVA and post-hoc multiple comparisons tests were performed to identify 
significant differences. In A–C, *P < 0.001 (cf. Basal group) and #P < 0.001 (cf. IL1β stimulated group); in D, *P = 0.003 (cf. Basal 
group) and #P < 0.001 (cf. IL1β stimulated group) and in E–F, *P < 0.0001 (cf. Basal group) and #P < 0.0001 (cf. IL1β stimulated 
group). 
  
H2S compounds also reduce IL6 levels and mRNA expression 
IL6 levels were increased due to stimulation with IL1β (184.3 (146.6, 222.1) ng/ml vs 106 (36, 176) 
pg/ml in the unstimulated cells). Measured levels decreased in cells co-stimulated with IL1β and NaSH or 
GYY4137. The best results were obtained for concentrations 1,000 μM NaSH (86.2 (65.2, 151.5) ng/ml) 
and 1,000 μM GYY4137 (89.1 (57.13, 121.1) ng/ml) [Fig. 3(A) and (B)]. Similar results were obtained 
for the mRNA expression levels; IL6 expression was also induced by IL1β (7,743 (3,250, 18,447)) and 
co-stimulation with the H2S sources reduced it in a dose-dependent manner. In this case, both 1,000 μM 
NaSH and GYY4137 were the best concentrations and their values were significant reductions from the 
IL1β value (616.0 (33.2, 11,430) and 543.3 (34.6, 8,540) vs Basal, respectively) [Fig. 3(C) and (D)]. 
 
 
 
Fig. 3. Interleukin-6 levels (measured with a specific ELISA, A-B) and mRNA expression (by qRT-PCR, C, D) were both reduced 
in IL1β-stimulated CHs after treatment with different concentrations of NaSH (A, C) and GYY4137 (B, D). For the ELISA 
experiments, values are mean and 95% CI (Lower limit, upper limit, n = 3, with duplicate measurement). For the qRT-PCR, values 
were calculated with qBase + software, n = 4 with duplicate technical repeats. One way ANOVA was performed followed by a post-
hoc multiple comparisons tests, except in B where a Kruskal–Wallis rank sum test followed by multiple comparisons was 
performed. For A, C and D *P < 0.0001 (cf. Basal group) and #P < 0.0001 (cf. IL1β stimulated group); for B *P < 0.001 (cf. Basal 
group) and #P < 0.001 (cf. IL1β stimulated group). 
H2S compounds show anti-catabolic properties 
We also looked at the effects of H2S compounds on MMP-13 production. Interleukin-1β increased 
MMP13 levels to 44.1 (26.7, 61.6) ng/ml (Basal level was 556 (438, 674) pg/ml, n = 3, performed in 
duplicate) that were subsequently reduced to 33.5 (22.1, 44.9) ng/ml for 1,000 μM NaSH and 17.3 (9.9, 
24.6) ng/ml for 1,000 μM for GYY3147 [ Fig. 4]. Also due to the IL1β addition, MMP13 mRNA 
expression increased up to 48.4 (17.7, 132.2) (fold vs Basal) [ Fig. 4(C) and (D)]. For both NaSH and 
GYY4137, 1,000 μM was the most efficacious concentration in reducing MMP13 expression (down to 
12.2 (3.6, 42.0)) for NaSH, and 8.2 (1.68, 40.1) for GYY4137 [ Fig. 4(C) and (D)]. Also at the protein 
level in ICC, MMP13 levels were clearly decreased by co-stimulation with both H2S-sources [ Fig. 4(E)–
(M)]. 
  
 
 
 
Fig. 4. Addition of NaSH (A, C) and GYY4137 (B, D) to IL1β stimulated CHs resulted in reduced MMP13 production, measured 
with a specific ELISA (A and B), reduced MMP13 gene expression by qRT-PCR (C and D), and in less MMP13 protein 
accumulation, by ICC (E–M). Values are mean and 95% CI (Lower limit, upper limit, n = 3, with duplicates). One way ANOVA 
and a post-hoc multiple comparisons test were performed to identify significant differences, except in A where a Kruskal–Wallis 
rank sum test followed by multiple comparisons was done. ICC images include IL1β-stimulated CHs (G) treated with different 
concentrations of NaSH (H–J) and GYY4137 (K–M). A negative ICC control (without primary antibody (E)), as well as 
unstimulated cells (F), was included for comparison. For B–D *P < 0.0001 (cf. Basal group) and #P < 0.0001 (cf. IL1β stimulated 
group), and for A *P < 0.00467 (cf. Basal group) and #P < 0.00467 (cf. IL1β stimulated group). 
  
H2S compounds reduce NFκB p65 translocation to the nucleus 
In an attempt to elucidate the possible mechanism by which H2S might be exerting the observed effects, 
an immunofluorescence assay was performed to visualize NFκB p65 nuclear translocation in the cells. 
Results are included in Fig. 5. In the basal condition, p65 was located mostly in the cytoplasms of the 
cells [Fig. 5(A)]. Stimulation with IL1β resulted in the translocation of p65 to the nuclei of the cells, as 
can be clearly seen in Fig. 5(B). Co-stimulation with the different concentrations of H2S compounds 
resulted in a reduction in the fluorescence intensity in the nuclei [Fig. 5(C)–(G), for GYY4137 and 
Fig. 5(H)–(L) for NaSH], although p65 could still be seen in the nuclei and the basal condition was not 
recovered. 
 
 
 
Fig. 5. Immunofluorescence images of NFκB p65 protein in IL1β stimulated CHs (45 min). In the basal condition (no stimulation) 
p65 can be seen mostly in the cells cytoplasms. IL1β stimulation lead to p65 translocation to the nuclei and the different 
concentrations of GYY4137 (C–G) and NaSH (H–L) resulted in a slight reduction of the nuclear fluorescence intensity, although 
p65 can still be seen in the nuclei and the basal situation was not fully recovered. 
Discussion 
This paper evaluates the ability of two exogenous H2S sources as anti–inflammatory and anti–catabolic 
agents in human articular CHs. Interleukin-1β was used as prototype pro-inflammatory cytokine to 
reproduce the “OA-like effect” in the cells. As expected5 and 6, the stimulation of OA CHs with IL1β 
induced the production of markers of inflammation and catabolic activity such as NO, PGE-2, IL6 and 
MMP13. 
NO is a multifunctional molecule that mediates various biological processes and is a well-known 
mediator in OA. It has been reported that OA CHs die by NO-induced apoptosis21, that OA CHs produce 
NO spontaneously23 and that human articular CHs express NOS2 when stimulated in culture24. Later 
studies reported that the most direct effect of NO in CHs seemed to be the suppression of energy 
metabolism25, but it has also been suggested that NO can inhibit matrix synthesis by CHs26. Our results 
show a dose-dependent reduction of NO levels and the inducible synthesis enzyme, NOS2, with both 
NaSH and GYY4137. Our GYY4137 results are in line with those recently published for 
lipopolysaccharide (LPS)-activated hCHs18 treated with this compound, but those of NaSH contradict a 
recent publication27 in which its use led to an increase in NO and NOS2 in rat vascular smooth muscle 
cells. Also, another study described that NaSH had a biphasic effect and at high concentrations (>200 μm) 
increased the synthesis of NO in a macrophage cell line28. Some authors reported that H2S can react 
directly with ROS and reactive nitrogen species (RNS)12, 29 and 30 which might account for part of the 
reduction they observed in NO, but in our case the NO decline is accompanied by a downregulation of the 
NOS2 gene and a reduction in the NOS2 protein. Therefore the reduction in NO cannot only be the result 
of a redox reaction and our results in the present in vitro model suggest that the H2S compounds can 
directly regulate the NOS2 gene. 
The role of H2S in inflammatory signaling has not been elucidated yet. Many reports attribute H2S 
both pro- and anti-inflammatory properties depending on the pathology studied, the experimental model 
used or the source of H2S
13 and 31. 
The effects of NaSH and GYY4137 on the release of pro- and anti-inflammatory mediators in LPS-
treated murine RAW264.7 macrophages were recently investigated28. GYY4137 inhibited LPS-induced 
release of pro-inflammatory mediators IL1β, IL6, TNF-α, and PGE-2 by increasing the anti-inflammatory 
chemokine IL-10. In contrast, NaSH had a biphasic effect and at high concentrations (>200 μm) increased 
the synthesis of IL1β, IL6, TNF-α, and PGE-2. On the other hand, reductions in PGE-2 and COX2 levels 
were also found in LPS–activated normal human fibroblast-like synoviocytes (hFLS) and hCHs18. 
Our results show a dose-dependent reduction in COX2 for both H2S sources. COX2 is considered the 
“inducible” COX isoform, activated by many factors, and current anti-inflammatory therapy for OA 
makes use of COX2 inhibitors. These unfortunately, have other disadvantages, including an 
accompanying inhibition of physiologic COX132. In the present results, COX2 inhibition was achieved at 
the highest H2S-compound concentration used, without significantly affecting COX1 (results not shown). 
In addition, our results also show a reduction of PTGES gene expression due to the H2S co-stimulation. 
PTGES was demonstrated as a key enzyme in the regulation of PGE-2 production in cytokine stimulated 
CHs from patients with OA9, suggesting that the terminal PG synthase downstream of COX is important 
for deciding which PG is synthesized, and that the induction of PTGES might be necessary for substantial 
PGE-2 production by CHs in response to pro-inflammatory stimuli. Therefore, the H2S-sources can 
regulate the two most important enzymes implicated in PGE-2 production in activated hCHs. 
Furthermore, in our model, IL6 production was stimulated by IL1β and the co-stimulation with H2S-
releasing compounds both downregulated IL6 gene mRNA expression and reduced IL6 levels produced 
by the cells. Two different studies have recently showed that NaSH could transiently block IL6 
expression, first in RA fibroblast-like synoviocytes33 and later in a CH cell line C-28/I234. IL6 can show 
both pro-inflammatory and anti-inflammatory effects (since, by itself, it can induce the production of 
tissue inhibitor of metalloproteinase, TIMP, but not MMPs) but IL1-induced IL6 is required for the 
inhibition of proteoglycan synthesis by IL1 in human articular cartilage35; also IL6 is synergistically 
responsible for IL1–induced MMPs increases6 and IL6 or its receptor are therapeutic targets for OA36. 
Therefore, the H2S-sources as used here can further reduce inflammation by regulating IL6 gene 
expression, resulting in lower free IL6 cytokine released by the cells. 
Collagenase 3 (MMP13) is the major type II collagen-degrading collagenase. It is regulated by stress-, 
inflammation- and differentiation-induced signals. Work by Goldring and colleagues recently reviewed10 
has singled out MMP13 as the key gene upon which many of the signaling pathways (i.e., NFκB, JNK or 
p38 MAPK) and transcription factors (such as NFκB, HIF2α, Ihh, or Runx2) involved at the different 
stages of OA converge. Most of these regulatory factors directly or indirectly, impact on MMP13 
transcription and activity. In our model, 1,000 μM of the two H2S-compounds used, reduced MMP13 
below the IL1β-induced levels at the mRNA and at the protein level also. There are, to the best of our 
knowledge, no other reports available on the effects of NaSH or GYY4137 on MMP13 activity on human 
osteoarthritic CHs. However, it has been reported that NaSH (20 min, 1 mM) upregulated the expression 
of the MMP3 gene in RA-FLS, while MMP3 was not detected at the mRNA level in the OA-FLS37. On 
the other hand, DAS, an oil-soluble organosulfur compound extracted from garlic, reduced MMP13 
synthesis in IL1β-activated rabbit CHs38. 
Additionally, the H2S compounds used in the present model seem to reduce the translocation of NFκB 
to the CHs nuclei, although not to prevent it completely. Activation of NFκB is directly responsible for 
the upregulation of several proinflammatory cytokines and enzymes, including NOS2, COX2 and 
IL618 and 19, so it is a plausible mechanism of action for NaSH and GYY4137. Nevertheless further studies 
are needed to confirm H2S implication in the NFκB signaling pathway and to investigate what other 
signaling routes might be implicated. 
Collectively, our results show that supplementation with exogenous H2S taps on important markers in 
OA and indicate that OA cartilage might benefit from the exogenous supplementation of H2S. However, 
the current results obtained in vitro might not translate to an in vivo situation, and this should be tested 
directly. Nevertheless, current data should grant further study into the implication of H2S, both 
exogenously added and/or endogenously controlled, in OA as a potential therapeutic target.  
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